Citigroup
MLTX icon

Citigroup’s MoonLake Immunotherapeutics MLTX Stock Holding History

Citigroup’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-30,000
Closed -$1.17M – 5813
2025
Q1 		$1.17M Buy
30,000
+5,000
+20% +$215K ﹤0.01% 3138
2024
Q4 		$1.35M Buy
+25,000
New +$1.28M ﹤0.01% 3121
2024
Q1 		– Sell
-24,900
Closed -$1.5M – 5775
2023
Q4 		$1.5M Buy
+24,900
New +$1.28M ﹤0.01% 2491

Other funds holding MLTX

Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Congress Asset Management
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
Zurich Cantonal Bank
Zurich Cantonal Bank Zurich, Switzerland $53.5B AUM 32.01% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Citigroup's MLTX Position: Q3 2026 in Review

Citigroup increased its MoonLake Immunotherapeutics (MLTX) stake by 1,018% in Q3 2026, buying an estimated $226K and bringing the position to 15,181 shares worth $178K. The position accounts for ﹤0.01% of the portfolio, ranked #4263.

Citigroup first reported a position in MLTX in Q2 2022 and has held it in 15 quarters since. The position peaked at $1.75M in Q4 2022. 56 funds tracked by Wall St. Rank hold MLTX as of Q3 2026.

  • Citigroup held 15,181 shares of MoonLake Immunotherapeutics worth $178K as of Q3 2026.
  • Citigroup bought 13,823 MoonLake Immunotherapeutics shares in Q3 2026, an estimated $226K.
  • MoonLake Immunotherapeutics made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #4263 holding.
  • Citigroup first reported a position in MoonLake Immunotherapeutics in Q2 2022 and has held it in 15 quarters since.
  • Citigroup's MoonLake Immunotherapeutics position peaked at $1.75M in Q4 2022.
  • 56 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.